Phase II trial of the ultra-rapid-acting insulins, BIOD 105 and BIOD 107, compared with insulin lispro, in patients with diabetes mellitus.

Next Previous
Trial Profile

Phase II trial of the ultra-rapid-acting insulins, BIOD 105 and BIOD 107, compared with insulin lispro, in patients with diabetes mellitus.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2011

At a glance

  • Drugs Insulin; Insulin lispro
  • Indications Diabetes mellitus
  • Focus Therapeutic Use

    • Most Recent Events

    • 27 Sep 2011 Status changed from planning to discontinued.
    • 15 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top